ReviewInternational journal of nephrology2023
The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge.
Review in International journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07309094. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in predicting chronic kidney disease prognosis. A systematic review and meta-analysis.Renal failure · 2024Pooled it
- The effect of stress ball use on stress, sleep quality, and comfort in individuals receiving hemodialysis: a randomized controlled trial.BMC complementary medicine and therapies · 2026Trial
- The Effect of progressive muscle relaxation and physical exercises on subjective well-being and fatigue of patients receiving hemodialysis: a randomized clinical trial.Scientific reports · 2025Trial
- Managing Early-Stage Chronic Kidney Disease: A Qualitative Study of Patients' and Healthcare Professionals' Perspectives.Nursing & health sciences · 2026Article
- Sex-Specific Associations of Monocyte-Based Inflammatory Indices with Renal Dysfunction and Hyperuricemia in the Saudi General Adult Population.Healthcare (Basel, Switzerland) · 2026Article
- Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.Kidney medicine · 2026Article
- Understanding the healthcare services and social support needs of patients with end-stage kidney disease in Ghana.BMC nephrology · 2026Article
- Observational
- Caloric Restriction Mimetic Hydroxycitrate Mitigates Acute Nephrotoxicity via Autophagy Activation and Oxidative Stress Reduction.Biomolecules · 2026Article
- Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost-Utility Analysis.Nutrients · 2026Article
- Prevalence and management of renal impairment in adults with type 2 diabetes mellitus in general versus specialized diabetes clinics in primary care in Kingdom of Bahrain.Journal of family medicine and primary care · 2026Article
- A Systematic Review Evaluating Estimated GFR Performance in South Asian Populations.Kidney international reports · 2026Article
- Proton Pump Inhibitors and Risk of Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Chronic kidney disease progression rate and predictors in hypertensive patients: A 5-year retrospective follow-up study in Ethiopia.PloS one · 2026Article
- Article
- Quantifying ultrasound echogenicity difference for accurate chronic kidney disease diagnosis.Journal of nephrology · 2025Article
- Reliability and validity of the preparatory grief scale for use with hemodialysis patients.World journal of psychiatry · 2025Article
- Article
- New biomarkers of inflammation associated with haemodialysis.Clinical kidney journal · 2025Article
- Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is becoming one of the world's most prevalent noncommunicable chronic diseases. The World Health Organization projects CKD to become the 5th most common chronic disease in 2040. Causes of CKD are multifactorial and diverse, but early-stage symptoms are often few and silent. Progression rates are highly variable, but patients encounter both an increased risk for end-stage kidney disease (ESKD) as well as increased cardiovascular risk. End-stage kidney disease incidence is generally low, but every single case carries a significant burden of illness and healthcare costs, making prevention by early intervention both desirable and worthwhile. This review focuses on the prevalence, diagnosis, and causes of CKD. In addition, we discuss the developments in the general treatment of CKD, with particular attention to what can be initiated in general practice. With the addition of recent landmark findings and the expansion of the indication for using sodium-glucose cotransporter 2 inhibitors, there are now new effective treatments to add to standard therapy. This will also be relevant for primary care physicians as many patients with CKD have their family physician as their primary health care professional handling kidney function preservation. In the future, more precise and less invasive diagnostic methods may not only improve the determination of the underlying cause of CKD but may also carry information regarding which treatment to use (i.e. personalized medicine). This could lead to a reduced number of preventive treatments per individual, while at the same time improving the prognosis. This review summarizes ongoing efforts in this area.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.